UPDATE: On Primary Endpoint, Anifrolumab Achieved Statistically Significant & Clinically Meaningful Reduction In Disease Activity At Week 52; 47.8% Of Patients Receiving Anifrolumab Responded Compared With 31.5% Of Patients On Placebo